임상 한눈에 보기

• 31건의 ClinicalTrials.gov 임상 기록
• Phase·Status 요약은 enrollment 상위 표본 기준입니다
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 2 · Phase 3 · Phase 1, Phase 2 · Phase 1
• Status: Recruiting · Active, not recruiting · Completed
• 주요 endpoint: Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry. · Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR) · Overall Survival (OS) · Percentage of Participants With Objective Response Rate (ORR) Per RECIST v1.1 by BICR · Time to Pain Progression (TTPP)
• 등록된 결과: ORR 25%
• 핵심: The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizum…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.